所有图片(1)
About This Item
经验公式（希尔记法）:
C15H11BrNNaO3
CAS号:
分子量:
356.15
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
![[2-Amino-3-(4-bromobenzoyl)phenyl]acetic acid](/deepweb/assets/sigmaaldrich/product/structures/595/049/7a5e8bce-ddce-46b3-8828-650aef0207d8/640/7a5e8bce-ddce-46b3-8828-650aef0207d8.png)
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
faintly yellow to dark yellow
溶解性
H2O: ≥5 mg/mL
储存温度
2-8°C
SMILES字符串
[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2
InChI
1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1
InChI key
HZFGMQJYAFHESD-UHFFFAOYSA-M
基因信息
human ... PTGS1(5742) , PTGS2(5743)
应用
溴芬酸钠可用于：
- 研究其与黑色素的结合能力
- 合成溴芬酸吲哚二酮标准物
- 分析其在猪结膜中的渗透性
生化/生理作用
溴芬酸展示解热和抑制前列腺素合成酶的特性。它对缓解术后白内障患者的眼痛和炎症有治疗作用。溴芬酸是对抗变应性结膜炎的有效药剂。它有望成为治疗急性肌肉疼痛、骨关节炎和类风湿性关节炎的良药。
溴芬酸是一种非甾体抗炎药（NSAID）；COX1 和 COX2 抑制剂；眼科止痛药。
溴芬酸是一种非甾体类抗炎药（NSAID），可同时抑制 COX1 和 COX2。它用作眼科止痛药。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Steven M Silverstein et al.
Current medical research and opinion, 27(9), 1693-1703 (2011-07-15)
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% dosed once daily for the treatment of ocular inflammation and pain following cataract extraction with posterior chamber intraocular lens implantation. A total of 455 subjects (455 study eyes:
Naoko Endo et al.
Acta ophthalmologica, 88(8), 896-900 (2009-09-04)
To compare the efficacy of bromfenac sodium ophthalmic solution (BF) and a steroidal solution (ST) administered prophylactically against cystoid macular oedema and anterior-chamber inflammation after phacoemulsification and intraocular lens implantation and to assess macular thickness changes using optical coherence tomography
James P Driscoll et al.
Chemical research in toxicology, 31(4), 223-230 (2018-03-24)
Bromfenac is a nonsteroidal anti-inflammatory drug that was approved in the United States in 1997. It was withdrawn from clinical use less than one year later, in 1998, due to hepatotoxicity. We investigate the potential of bromfenac to be metabolized
Frank A Bucci et al.
Advances in therapy, 28(12), 1089-1095 (2011-11-23)
We compared the prostaglandin E(2) (PGE(2)) inhibition of three topical nonsteroidal antiinflammatory drugs (NSAIDs): ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% at peak dosing levels in patients previously scheduled to undergo phacoemulsification. This was a single-center, double-masked observational study of
Jeffrey S Heier et al.
Retina (Philadelphia, Pa.), 29(9), 1310-1313 (2009-11-26)
To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy. This was an investigator-masked, randomized, multicenter study. Patients received ketorolac 0.4% 4 times a day, bromfenac 0.09% 2 times a day
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门